ClinicalTrials.gg
Status unknownNCT04325776Updated Oct 12, 2020

A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis

A Phase 2 interventional study of AL2846 and Zoledronic Acid Injection in Bone Metastatic Non-small Cell Lung Cancer, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-12.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited — 8 open to participants now, 8 under way, 4 of them phase 3. Carcinoma, Non-Small-Cell Lung · Sino Biopharmaceutical Limited.

Planned enrollment
21st of 27
60 · median 117
Started
2020
with 6 others
Phase 2
7 of 27
2 open now
Registered
10th of 27
by date

Among the 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited, this one is the 21st largest by planned enrollment, is one of 7 that started in 2020, is one of 7 in phase 2, and was the 10th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

8 of the 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Carcinoma, Non-Small-Cell Lung by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met, suggesting that its anti-tumor effect mainly inhibits the activation of key downstream oncogenic pathways by inhibiting expression of c-met, tumor angiogenesis and tumor cell migration.

03

Conditions studied

  • Bone Metastatic Non-small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Understood and signed an form. 2.18 years and older; (ECOG) performance status of 0 to 1; ≥ 3 months.

    3. confirmed advanced non-small cell lung cancer with at least one bone lesion with bone destruction.

    4.Has received at least two systematic treatment regimens that failed or were unable to tolerate treatment.

    5.EGFR, ALK gene mutations are negative. 6.Adequate laboratory indicators. 7.No pregnant or breastfeeding women, and a negative pregnancy test.

Exclusion criteria

Exclusion Criteria:

  • 1.Small cell lung cancer. 2. Diagnosed and/or treated additional within 5 years with the exception of cured cervical carcinoma in situ and non-melanoma skin cancer.

    1. Has received radiotherapy, chemotherapy and surgery before and less than 4 weeks from the first administration and less than 5 half-lives of oral targeted drugs after the completion of treatment.
    1. Has received systemic radionuclide therapy or semi-extracorporeal radiation for bone .
    1. Has known to be allergic to the study drug or any of its . 6. Has symptomatic , spinal cord compression, and cancerous meningitis within 8 weeks,or brain or pia mater disease confirmed by CT or MRI examination before the first dose.
    1. Has adverse events caused by previous therapy that did not recover to ≤ grade 1, with the exception of alopecia or ≥ grade 2 neurotoxicity caused by Oxaliplatin.
    1. Imaging (CT or MRI) shows that tumor invades large blood vessels or the boundary with blood vessels is unclear.
    1. Has spinal cord compression or mandibular osteonecrosis. 10.Has multiple factors that affect oral medications. 11.Has gastroduodenal ulcer, ulcerative colitis, intestinal obstruction and other gastrointestinal diseases or other conditions judged by the investigator that may cause gastrointestinal bleeding or perforation.

    12.Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.

    1. Has severe acute comorbidities before the first dose. 14. Has participated in other clinical trials within 4 weeks before the first dose.

    15.According to the investigators' judgment.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    AL2846+An analog of zoledronic acid injection

    AL2846 capsules 150 mg given orally, once daily in 28-day cycle, an analog of zoledronic acid injection (5ml:0mg) administered intravenously (IV) on Day 1 of each 28-day cycle.

    Drug: AL2846

  • Active comparator
    An analog of AL2846+ zoledronic acid injection

    An analog of AL2846 capsules 0 mg given orally, once daily in 28-day cycle, zoledronic acid injection (5ml:4mg) administered intravenously (IV) on Day 1 of each 28-day cycle.

    Drug: Zoledronic Acid Injection

Interventions

  • DrugAL2846

    AL2846 is a multi-target tyrosine kinase receptor inhibitor with obvious selective to c-met.

  • Zoledronic acid is a bisphosphonate drug that has a strong inhibition of bone resorption and a potential to promote bone formation, and can be used for bone metastasis caused by malignant tumors.

06

What researchers measure

Primary outcomes

  1. The time when the first bone-related event (SRE) occurred

    The time from the randomization to the first occurrence of any meeting of bone-related event criteria.

    Time frame: up to 96 weeks

Secondary outcomes

  1. Overall survival (OS)

    OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.

    Time frame: up to 96 weeks

  2. Progression-free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on investigator.

    Time frame: up to 96 weeks

  3. Overall response rate (ORR)

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: up to 96 weeks

  4. Duration of Response (DOR)

    The time when the participants first achieved complete or partial remission to disease progression.

    Time frame: up to 96 weeks

  5. Disease control rate(DCR)

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: up to 96 weeks

  6. Effectiveness of improving average daily pain intensity on week 8 and 16 (Refer to Brief pain inventory (BPI) and the Verbal rating scale (VRS)

    Referring to Brief pain inventory (BPI) and Verbal rating scale (VRS), the percentage of improvement in the average intensity of pain confirmed at week 8 and week 16 compared to the previous average intensity.

    Time frame: on 8 and 16 week

  7. Biomarkers

    Relationship between drug efficacy and related biomarkers such as C-Met, FGFR, c-Kit, RET.

    Time frame: up to 96 weeks

07

Study locations

6 of 8 sites recruiting
  • Anhui Chest Hospital
    Hefei, Anhui 230000, China
    Recruiting
    • Xuhong Min, Doctor · Contact1320722827@qq.com
    • Xuhong Min, Doctor · Principal investigator
  • Henan Cancer Hospital
    Zhengzhou, Henan 450008, China
    Recruiting
    • Suxia Luo, Doctor · Contactluosxrm@163.com
    • Suxia Luo, Doctor · Principal investigator
  • China-Japan Union Hospital Of Jilin University
    Changchun, Jilin 130031, China
    Not yet recruiting
    • Yuansong Bai, Master · Contactbaiyuansong@163.com
    • Yuansong Bai, Master · Principal investigator
  • Jinzhou Central Hospital
    Jinzhou, Liaoning 121001, China
    Recruiting
  • Shenyang Chest Hospital
    Shenyang, Liaoning 110044, China
    Recruiting
    • Yinyin Li, Doctor · Contact847226789@qq.com
    • Yinyin Li, Doctor · Principal investigator
  • Sir Run Run Shaw Hospital (SRRSH)
    Hangzhou, Zhejiang 310020, China
    Recruiting
    • Hongming Pan, Doctor · Contactshonco@sina.cn · 0571-86006922
    • Hongming Pan, Doctor · Principal investigator
  • The First Hospital of Jiaxing
    Jiaxing, Zhejiang 314001, China
    Not yet recruiting
  • Quzhou People's Hospital
    Quzhou, Zhejiang 324000, China
    Recruiting
    • Qinhong Zheng, Master · Contactzqh180@126.com
    • Qinhong Zheng, Master · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2020 (actual). Primary completion is estimated for May 2021, 8 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 8 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2020
First posted
Mar 30, 2020
StartActual
Sep 24, 2020
Primary completionEst.
May 2021
CompletionEst.
Nov 2021
Last update
Oct 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04325776
Responsible party
Sponsor
First posted
Mar 30, 2020
Start date
Sep 24, 2020
Primary completion
May 2021 (estimated)
Completion
Nov 2021 (estimated)
Last update
Oct 12, 2020

Study contacts

Hongming Pan, Doctor
Contact
shonco@sina.cn
0571-86006922

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vilzemetkib

Start the discussion